CAR T Cell Therapy Market

CAR T-cell therapy market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Antigens (CD19, BCMA, CD20, CD19/22, and Other Target Antigens), Target Indication (Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, and Others), Key Geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World), Sales Forecast of Drugs and Leading Players

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    554

  • Pages
    598

  • View Count
    38825

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of T-cell Immunotherapies
5.2.1. Historical Evolution
5.2.2. Key Considerations for Developing T-cell Immunotherapies
5.2.3. Strategies Employed for the Redirection of T-cells
5.2.4. Manufacturing of Engineered T-cells

5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
5.3.1. Development History

5.3.2. Structure of CAR
5.3.2.1. Ectodomain
5.3.2.2. Transmembrane (TM) Domain
5.3.2.3. Endodomain

5.3.3. Development of CAR-T Cells
5.3.4. Universal CAR-T Cells
5.3.5. Route of Administration

5.3.6. Challenges Associated with CAR-T Cell Therapies
5.3.6.1. Competitive Risks
5.3.6.2. Clinical Risks
5.3.6.3. Regulatory Risks
5.3.6.4. Commercial Risks

5.4. Concluding Remarks

6. CAR-T CELL THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Market Landscape
6.2.2. Analysis by Stage of Development
6.2.3. Analysis by Type of Therapy
6.2.4. Analysis by Target Antigen
6.2.5. Analysis by Target Indication
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Stage of Development and Therapeutic Area
6.2.8. Analysis by Source of T-cells
6.2.9. Analysis by Stage of Development and Source of T-cells
6.2.10. Analysis by Route of Administration
6.2.11. Analysis by Dosage Regimen
6.2.12. Analysis by Target Patient Population
6.2.13. Most Active Industry Players: Analysis by Number of Therapies
6.2.14. Most Active Non-Industry Players: Analysis by Number of Therapies

6.3. CAR-T Cell Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Popular Target Antigens
7.2.1. Popular Targets for Hematological Malignancies
7.2.2. Popular Targets for Solid Tumors

7.3. CAR-T Therapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody Used
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Type of Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
8.3.3. Analysis by Trial Phase
8.3.4. Analysis of Enrolled Patient Population by Trial Phase
8.3.5. Analysis by Trial Registration Year and Trial Phase
8.3.6. Analysis by Trial Status
8.3.7. Analysis by Patient Gender
8.3.8. Analysis by Therapeutic Area
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.13. Analysis by Geography

9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology

9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Geographical Location of KOLs
9.4.4. KOL Activeness versus KOL Strength
9.4.5. Most Prominent KOLs: Analysis by RA score
9.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. COMPANY PROFILES
10.1. Chapter Overview
10.2. Autolus
10.3. Bluebird Bio
10.4. Bristol Myers Squibb
10.5. CARsgen Therapeutics
10.6. Cellectis
10.7. Gilead Sciences
10.8. Innovative Cellular Therapeutics
10.9. Noile-Immune Biotech
10.10. Novartis
10.11. Sinobioway Cell Therapy
10.12. Takara Bio
10.13. Wellington Zhaotai Therapies

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models

11.3. CAR-T Cell Therapies: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Partner
11.3.5. Most Popular Therapies: Analysis by Number of Partnerships
11.3.6. Most Active Industry Players: Analysis by Number of Partnerships
11.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

11.3.8. Analysis by Geography
11.3.8.1. Intercontinental and Intracontinental Agreements
11.3.8.2. International and Local Agreements

12. FUNDING AND INVESTMENTS ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding

12.3. CAR-T Cell Therapies: Funding and Investment Analysis
12.3.1. Analysis by Year of Funding
12.3.2. Analysis of Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Amount Invested and Type of Funding
12.3.5. Analysis by Amount Invested by year and Type of Funding Analysis by Type of Investor
12.3.6. Analysis by Geography
12.3.7. Most Active Players
12.3.8. Leading Investors: Analysis by Number of Funding Instances

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology

13.3. CAR-T Cell Therapies: Patent Analysis
13.3.1. Analysis by Patent Publication Year
13.3.2. Analysis by Patent Application Year
13.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
13.3.4. Analysis by Patent Jurisdiction
13.3.5. Analysis by CPC Symbols
13.3.6. Analysis by Type of Applicant
13.3.7. Leading Industry Players: Analysis by Number of Patents
13.3.8. Leading Non-Industry Players: Analysis by Number of Patents
13.3.9. Leading Patent Assignees: Analysis by Number of Patents

13.4. Patent Benchmarking Analysis
13.4.1. Analysis by Patent Characteristics

13.5. Patent Valuation
13.6. Leading Patents by Number Of Citations

14. CASE STUDY: CELL THERAPY MANUFACTURING
14.1. Chapter Overview
14.2. Overview of Cell Therapy Manufacturing

14.3. Cell Therapy Manufacturing Models
14.3.1. Centralized Manufacturing Model
14.3.2. Decentralized Manufacturing Model

14.4. Scalability of Cell Therapy Manufacturing Processes
14.4.1. Scale-Up
14.4.2. Scale-Out

14.5. Types of Cell Therapy Manufacturers
14.6. Key Challenges Related to Manufacturing of Cell Therapies

14.7. Key Considerations for Cell Therapy Manufacturing
14.7.1. Characterization
14.7.2. Cost of Goods

14.8. Automation of Cell Therapy Manufacturing Process
14.9. Cell Therapy Manufacturing Supply Chain
14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
14.11. Regulatory Landscape
14.12. Future Perspectives

15. COST PRICE ANALYSIS
15.1 Chapter Overview
15.2. Factors Contributing to the High Price of Cell / Gene Therapies

15.3. Pricing Models for T-cell Immunotherapies
15.3.1. Based on Associated Costs
15.3.2. Based on Availability of Competing Products
15.3.3. Based on Patient Population
15.3.4. Based on Opinions of Industry Experts 

15.4. Reimbursement related Considerations for T-cell Immunotherapies
15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL CAR-T CELL THERAPY MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Future Estimates (2024-2035), till 2035

17.4. Scenario Analysis
17.4.1. Conservative Scenario
17.4.2. Optimistic Scenario

17.5. Key Market Segmentations

18. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
18.1. Chapter Overview
18.2. Key Assumptions and Methodology

18.3. CAR-T Cell Therapies Market: Distribution by Type Target Antigen, 2024 and 2035
18.3.1. CART-T Cell Therapies Market for CD19: Forecasted Estimates (2024-2035)
18.3.2. CART-T Cell Therapies Market FOR BCMA: Forecasted Estimates (2024-2035)
18.3.3. CART-T Cell Therapies Market FOR CD20: Forecasted Estimates (2024-2035)
18.3.4. CART-T Cell Therapies Market for CD19 / CD22: Forecasted Estimates (2025-2035)
18.3.5. CAR-T Cell Therapies Market for Other Target Antigens: Forecasted Estimates (2028-2035)

18.4. Data Triangulation and Validation

19. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology

19.3. CAR-T Cell Therapies Market: Distribution by Target Indication, 2024 and 2035
19.3.1. CAR-T Cell Therapies Market for Multiple Myeloma: Forecasted Estimates (2024-2035)
19.3.2. CAR-T Cell Therapies Market for Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
19.3.3. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035)
19.3.4. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
19.3.5. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma and Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
19.3.6. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia/ B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035)
19.3.7. CAR-T Cell Therapies Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035)
19.3.8. CAR-T Cell Therapies Market for Mantle Cell Lymphoma: Forecasted Estimates (2024-2035)
19.3.9. CAR-T Cell Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (2028-2035)
19.3.10. CAR-T Cell Therapies Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035)
19.3.11. CAR-T Cell Therapies Market for Renal Transplantation: Forecasted Estimates (2030-2035)
19.3.12. CAR-T Cell Therapies Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035)
19.3.13. CAR-T Cell Therapies Market for Ovarian / Endometrial cancer: Forecasted Estimates (2028-2035)
19.3.14. CAR-T Cell Therapies Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035)
19.3.15. CAR-T Cell Therapies Market for Follicular Lymphoma: Forecasted Estimates (2024-2035)
19.3.16. CAR-T Cell Therapies Market for Renal Cell Carcinoma: Forecasted Estimates (2028-2035)

19.6. Data Triangulation and Validation

20. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology

20.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024 and 2035
20.3.1. CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035)
20.3.2. CAR-T Cell Therapy Market for Europe: Forecasted Estimates (2024-2035)
20.3.3. CAR-T Cell Therapy Market for Asia-Pacific: Forecasted Estimates (2024-2035)
20.3.4. CAR-T Cell Therapy Market for Latin America: Forecasted Estimates (2024-2035)
20.3.5. CAR-T Cell Therapy Market for Middle East and North Africa: Forecasted Estimates (2024-2035)
20.3.6. CAR-T Cell Therapy Market for Rest of the World: Forecasted Estimates (2024-2035)

20.4. Data Triangulation and Validation

21. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology

21.3. Commercialized CAR-T Cell Therapies: Sales Forecast
21.3.1. Kymriah (Tisagenlecleucel-T) Sales Forecast
21.3.2. Yescarta (axicabtagene ciloleucel) Sales Forecast
21.3.3. Tecartus (Brexucabtagene Autoleucel) Sales Forecast
21.3.4. Abecma (Idecabtagene Vicleucel / bb211211) Sales Forecast
21.3.5. CARVYKTI (LCAR-B38M CAR-T / JNJ-6821845218 / Ciltacabtagene Autoleucel) Sales Forecast
21.3.6. BREYANZI (Lisocabtagene maraleucel, JCAR017) Sales Forecast
21.3.7. Carteyva (Relmacabtagene autoleucel / JWCAR0219) Sales Forecast
21.3.8. NexCART Sales Forecast
21.3.9. Fucaso (Equecabtagene Autoleucel) Sales Forecast
21.3.10. Inaticabtagene Autoleucel CNCT19 / HY001Sales Forecast
21.3.11. Zevorcabtagene autoleucel (CT053) Sales Forecast

21.4 Clinical CAR-T Cell Therapies: Sales Forecast
21.4.1. CAR-BCMA T cells Sales Forecast
21.4.2. CAR-T-CD19 Cells Sales Forecast
21.4.3. Descartes-08 Sales Forecast
21.4.4. Zamtocabtagene Autoleucel (MB-CART21019.1) Sales Forecast
21.4.5. CAR-T ddBCMA Sales Forecast
21.4.6. CRG-02121 cells Sales Forecast
21.4.7. CT041 Sales Forecast
21.4.8. ALLO-501A / ALLO-501 Sales Forecast
21.4.9. ALLO-605 Sales Forecast
21.4.10. Descartes-25 Sales Forecast
21.4.11. AUTO1 Sales Forecast
21.4.12. AUTO3 (CD19/2121 CAR-T) Sales Forecast
21.4.13. AUTO4 (CD19/2121 CAR-T) Sales Forecast
21.4.14. CD19-CAR-T Sales Forecast
21.4.15. Humanized CD19-CAR-T Sales Forecast
21.4.16. IM19 CAR-T Sales Forecast
21.4.17. CCT301 CAR-T Sales Forecast
21.4.18. CARCIK-CD19 Sales Forecast
21.4.19. CD123 CAR-T cells Sales Forecast
21.4.20. BCMA CAR-T Sales Forecast
21.4.21. CD19/CD22-CAR-T Sales Forecast
21.4.22. GC012F (Dual CAR-BCMA-19) Sales Forecast
21.4.23. CD19/CD210-CART Sales Forecast
21.4.24. CD7 CAR-T Sales Forecast
21.4.25. Anti-FLT3 CAR-T / TAA05 Sales Forecast
21.4.26. Anti-ALPP CAR-T Cells Sales Forecast
21.4.27. WU CART 007 Sales Forecast
21.4.28. CTX110 Sales Forecast
21.4.29. TX2100-TR101 Sales Forecast
21.4.30. ALETA-001 Sales Forecast
21.4.31. PBCAR0191 Sales Forecast

21.5. Data Triangulation and Validation

22. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. CAR-T Cell Therapies: Leading Players
22.3.1. Gilead Sciences Sales Forecast
22.3.2. Bristol Myers Squibb Sales Forecast
22.3.3. Novartis Sales Forecast
22.3.4. Janssen Sales Forecast
22.3.5. JW Therapeutics Sales Forecast
22.4. Data Triangulation and Validation

23. PROMOTIONAL ANALYSIS
23.1. Chapter Overview
23.2. Channels Used for Promotional Campaigns
23.3. Summary of Product Website Analysis
23.4. Summary of Patient Support Services and Informative Downloads

23.5. Kymriah: Promotional Analysis
23.5.1. Drug Overview
23.5.2. Product Website Analysis
23.5.2.1. Message for Healthcare Professionals
23.5.2.2. Message for Patients
23.5.2.3. Informative Downloads

23.5.3. Patient Support Services

23.6. Yescarta: Promotional Analysis
23.6.1. Drug Overview
23.6.2. Product Website Analysis
23.6.2.1. Message for Healthcare Professionals
23.6.2.2. Message for Patients
23.6.2.3. Informative Downloads

23.6.3. Patient Support Services

23.7. Tecartus: Promotional Analysis
23.7.1. Drug Overview

23.7.2. Product Website Analysis
23.7.2.1. Message for Healthcare Professionals
23.7.2.2. Message for Patients
23.7.2.3. Informative Downloads

23.7.3. Patient Support Services

23.8. Breyanzi: Promotional Analysis
23.8.1. Drug Overview

23.8.2. Product Website Analysis
23.8.2.1. Message for Healthcare Professionals
23.8.2.2. Message for Patients
23.8.2.3. Informative Downloads

23.8.3. Patient Support Services

23.9. Abecma: Promotional Analysis
23.9.1. Drug Overview

23.9.2. Product Website Analysis
23.9.2.1. Message for Healthcare Professionals
23.9.2.2. Message for Patients
23.9.2.3. Informative Downloads

23.9.3. Patient Support Services

23.10. Carvykti: Promotional Analysis
23.10.1. Drug Overview

23.10.2. Product Website Analysis
23.10.2.1. Message for Healthcare Professionals
23.10.2.2. Message for Patients
23.10.2.3. Informative Downloads

23.10.3. Patient Support Services

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Atara Biotherpeutics
24.2.1. Interview Transcript

24.3. Glycostem Therapeutics
24.3.1. Interview Transcript

24.4. Gracell Biotechnologies
24.4.1. Interview Transcript

24.5. TxCell
24.5.1 Interview Transcript

24.6. Kite Pharma
24.6.1. Interview Transcript

24.7. Celyad
24.7.1. Interview Transcript

24.8. Waisman Biomanufacturing
24.8.1. Interview Transcript

24.9. Theravectys
24.9.1. Interview Transcript

24.10. Changhai Hospital
24.10.1. Interview Transcript

24.11. Changhai Hospital
24.11.2. Interview Transcript

25. CONCLUDING REMARKS

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

28. APPENDIX III: LIST OF FUNDING AND INVESTMENTS 

List Of Figures

 Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Clinical Trial Analysis
Figure 4.3 Executive Summary: Funding and Investments
Figure 4.4 Executive Summary: Patent Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Strategies Employed for the Redirection of T-Cells
Figure 5.2 T-Cell Manufacturing: General Procedure
Figure 5.3 Development History of CAR-T cells
Figure 5.4 Structure of Chimeric Antigen Receptor
Figure 5.5 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 5.6 CAR-T Cell Therapies: Development Process
Figure 5.7 Challenges Associated with CAR-T-Cell Therapies
Figure 6.1 CAR-T Cell Therapies: Distribution by Stage of Development
Figure 6.2 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 6.2 CAR-T Cell Therapies: Distribution by Target Antigen
Figure 6.3 CAR-T Cell Therapies: Distribution by Target Indication
Figure 6.4 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 6.5 CAR-T Cell Therapies: Distribution by Stage of Development and Therapeutic Area
Figure 6.6 CAR-T Cell Therapies: Distribution by Source of T-cells
Figure 6.7 CAR-T Cell Therapies: Distribution by Stage of Development and Source of T-cells
Figure 6.8 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 6.9 CAR-T Cell Therapies: Distribution by Dosage Regimen
Figure 6.10 CAR-T Cell Therapies: Distribution by Target Patient Population
Figure 6.11 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 6.12 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 6.13 CAR-T Cell Therapies Developers: Distribution by Year of Establishment
Figure 6.14 CAR-T Cell Therapies Developers: Distribution by Company Size
Figure 6.15 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Region)
Figure 6.16 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Country)
Figure 7.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 7.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 7.3 CAR-Construction: Distribution by Generation of CAR
Figure 7.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.5 CAR-Construction: Distribution by Type of Virus Used
Figure 7.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Figure 8.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2017-2024
Figure 8.2 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year, Pre- 2017-2024
Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2017–2023
Figure 8.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 8.8 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 8.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 8.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 8.12 Clinical Trial Analysis: Distribution by Design Allocation
Figure 8.13 Leading Industry Players: Distribution by Number of Registered Trials
Figure 8.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 8.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 9.1 KOL Analysis: Distribution by Type of Organization
Figure 9.2 KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 KOL Analysis: Distribution by Qualification
Figure 9.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
Figure 9.5 CAR T-Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 Most Prominent KOLs: Distribution by RA Score
Figure 9.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 11.1. Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015- 2022
Figure 11.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5. Most Popular Therapies: Distribution by Number of Partnerships
Figure 11.6. Most Active Industry Players: Distribution by Number of Partnerships
Figure 11.7. Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 11.8. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 11.8. Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Pre 2014-2024
Figure12.2 Funding and Investment Analysis: Distribution by Amount Invested, Pre-2014-2024 (USD Million)
Figure12.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure12.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)
Figure12.5 Year-wise Distribution of Amount Invested by Type of Funding, 2018-2024
Figure 12.6 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 12.7 Funding and Investment Analysis: Distribution of Funding Instances by Geography (Country)
Figure 12.8 Most Active Players: Distribution by Funding Instances
Figure 12.9 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2018-2024
Figure 13.3 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2017-2024
Figure 13.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2018-2024
Figure 13.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.6 Patent Analysis: Distribution by CPC Symbols
Figure 13.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 13.8 Leading Industry Players: Distribution by Number of Patents
Figure 13.9 Leading Non-industry Players: Distribution by Number of Patents
Figure 13.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 13.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.13 Patent Analysis: Distribution by Patent Age
Figure 13.14 CAR-T Cell Therapy: Patent Valuation
Figure 14.1 Steps for Manufacturing Cell Therapies
Figure 14.2 Centralized Manufacturing: Process Model
Figure 14.3 Decentralized Manufacturing: Process Model
Figure 14.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 14.5 Cell Therapy: Challenges and Drivers
Figure 14.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 14.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 14.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 15.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 16.1. CAR-T Cell Therapies: Market Drivers
Figure 16.2. CAR-T Cell Therapies: Market Restraints
Figure 16.3. CAR-T Cell Therapies: Market Opportunities
Figure 16.4. CAR-T Cell Therapies: Market Challenges
Figure 17.1. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.2. Global CAR-T Cell Therapy Market, 2024-2035: Conservative Scenario (USD Million)
Figure 17.3. Global CAR-T Cell Therapy Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 18.1. CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024 and 2035
Figure 18.2. CAR-T Cell Therapy Market for CD19: Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.3. CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.4. CAR-T Cell Therapy Market for CD20: Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.5. CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (2025-2035) (USD Billion)
Figure 18.6. CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (2028-2035) (USD Billion)
Figure 19.1. CAR-T Cell Therapy Market: Distribution by Target Indication, 2024 and 2035
Figure 19.2. CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.3. CAR-T Cell Therapy Market for CAR-T Cell Therapies Market for Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.4. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.5. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.6. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma and Large B-cell Lymphoma: Forecasted Estimates (2024-2035 (USD Billion)
Figure 19.7. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035) (USD Billion)
Figure 19.8. CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.9. CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.10. CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.11. CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035) (USD Billion)
Figure 19.12. CAR-T Cell Therapy Market for Renal Transplantation: Forecasted Estimates (2030-2035) (USD Billion)
Figure 19.13. CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035) (USD Billion)
Figure 19.14. CAR-T Cell Therapy Market for Ovarian / Endometrial Cancer: Forecasted Estimates (2028-2035) (USD Billion)
Figure 19.15. CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035) (USD Billion)
Figure 19.16. CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.17. CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.1. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
Figure 20.2. CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.3. CAR-T Cell Therapy Market in Europe: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.4. CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.5. CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.6. CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.7. CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.1 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, 2024-2035 (USD Million)
Figure 21.2 CAR-T Cell Therapy Market for Yescarta (axicabtagene ciloleucel): Sales Forecast, 2024-2035 (USD Million)
Figure 21.3 CAR-T Cell Therapy Market for Tecartus (Brexucabtagene Autoleucel): Sales Forecast, 2024-2035 (USD Million)
Figure 21.4 CAR-T Cell Therapy Market for Abecma (Idecabtagene Vicleucel / bb2121): Sales Forecast, 2024-2035 (USD Million)
Figure 21.5 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38M CAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
Figure 21.6 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, 2024-2035 (USD Million)
Figure 21.7 CAR-T Cell Therapy Market for Carteyva (Relmacabtagene autoleucel / JWCAR029): Sales Forecast, 2024-2035, (USD Million)
Figure 21.8 CAR-T Cell Therapy Market for NexCART: Sales Forecast, 2024-2035, (USD Million)
Figure 21.9 CAR-T Cell Therapy Market for Fucaso (Equecabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
Figure 21.10 CAR-T Cell Therapy Market for Inaticabtagene Autoleucel CNCT19 / HY001: Sales Forecast, 2024-2035 (USD Million)
Figure 21.11 CAR-T Cell Therapy Market for Zevorcabtagene autoleucel (CT053): Sales Forecast, 2024-2035 (USD Million)
Figure 21.12 CAR-T Cell Therapy Market for CAR-BCMA T cells: Sales Forecast, 2027-2035 (USD Million)
Figure 21.13 CAR-T Cell Therapy Market for CAR-T-CD19 cells : Sales Forecast, 2026-2035 (USD Million)
Figure 21.14 CAR-T Cell Therapy Market for Descartes-08: Sales Forecast, 2029-2035 (USD Million)
Figure 21.15 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, 2028-2035 (USD Million)
Figure 21.16 CAR-T Cell Therapy Market for CAR-T ddBCMA: Sales Forecast, 2029-2035 (USD Million)
Figure 21.17 CAR-T Cell Therapy Market for CRG-02121 cells: Sales Forecast, 2030-2035 (USD Million)
Figure 21.18 CAR-T Cell Therapy Market for CT041: Sales Forecast, 2030-2035, (USD Million)
Figure 21.19 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501: Sales Forecast, 2032-2035, (USD Million)
Figure 21.20 CAR-T Cell Therapy Market for ALLO-605: Sales Forecast, 2028-2035 (USD Million)
Figure 21.21 CAR-T Cell Therapy Market for Descartes-25: Sales Forecast, 2029-2035 (USD Million)
Figure 21.22 CAR-T Cell Therapy Market for AUTO1: Sales Forecast, 2029-2035 (USD Million)
Figure 21.23 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T) : Sales Forecast, 2025-2035 (USD Million)
Figure 21.24 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T) : Sales Forecast, 2029-2035 (USD Million)
Figure 21.25 CAR-T Cell Therapy Market for CD19-CAR-T: Sales Forecast, 2026-2035 (USD Million)
Figure 21.26 CAR-T Cell Therapy Market for Humanized CD19-CAR-T: Sales Forecast, 2028-2035 (USD Million)
Figure 21.27 CAR-T Cell Therapy Market for IM19 CAR-T: Sales Forecast, 2027-2035 (USD Million)
Figure 21.28 CAR-T Cell Therapy Market for CCT301 CAR-T: Sales Forecast, 2028-2035 (USD Million)
Figure 21.29 CAR-T Cell Therapy Market for CARCIK-CD19: Sales Forecast, 2028-2035 (USD Million)
Figure 21.30 CAR-T Cell Therapy Market for CD123 CAR-T cells: Sales Forecast, 2028-2035 (USD Million)
Figure 21.31 CAR-T Cell Therapy Market for BCMA CAR-T: Sales Forecast, 2028-2035 (USD Million)
Figure 21.32 CAR-T Cell Therapy Market for CD19/CD22-CAR-T: Sales Forecast, 2029-2035 (USD Million)
Figure 21.33 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19): Sales Forecast, 2029-2035 (USD Million)
Figure 21.34 CAR-T Cell Therapy Market for CD19/CD20-CART: Sales Forecast, 2030-2035 (USD Million)
Figure 21.35 CAR-T Cell Therapy Market for CD7 CAR-T: Sales Forecast, 2029-2035 (USD Million)
Figure 21.36 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T / TAA05: Sales Forecast, 2030-2035 (USD Million)
Figure 21.37 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells: Sales Forecast, 2028-2035 (USD Million)
Figure 21.38 CAR-T Cell Therapy Market for WU CART 007: Sales Forecast, 2030-2035 (USD Million)
Figure 21.39 CAR-T Cell Therapy Market for CTX110: Sales Forecast, 2030-2035 (USD Million)
Figure 21.40 CAR-T Cell Therapy Market for TX200-TR101: Sales Forecast, 2030-2035 (USD Million)
Figure 21.41 CAR-T Cell Therapy Market for ALETA-001: Sales Forecast, 2030-2035 (USD Million)
Figure 21.42 CAR-T Cell Therapy Market for PBCAR0191: Sales Forecast, 2030-2035 (USD Million)
Figure 22.1. CAR-T Cell Therapies Market: Distribution by Key Players
Figure 22.2. CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, 2024-2035 (USD Million)
Figure 22.3. CAR-T Cell Therapies Market: Janssen Sales Forecast, 2024-2035 (USD Million)
Figure 22.4. CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, 2024-2035 (USD Million)
Figure 22.5. CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, 2024-2035 (USD Million)
Figure 22.6 CAR-T Cell Therapies Market: Novartis Sales Forecast, 2024-2035 (USD Million)
Figure 23.1 Channels Used for Promotional Campaigns
Figure 23.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 23.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 23.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 23.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 23.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 23.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 23.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 23.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 23.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 23.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 23.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 23.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 23.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 23.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 23.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 23.17 Product Website Analysis: Abecma, Messages for Patients
Figure 23.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 23.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 23.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 23.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 24.1 Concluding Remarks: Market Landscape
Figure 25.2 Concluding Remarks: Clinical Trial Analysis
Figure 25.3 Concluding Remarks: Funding and Investment Analysis
Figure 25.4 Concluding Remarks: Patent Analysis
Figure 25.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 5.1 Key Characteristics of CAR-T Cells
Table 5.2 Comparison of First and Second-Generation CAR-Ts
Table 6.1 CAR-T Cell Therapies: Approved and Clinical Pipeline
Table 6.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-cell, Dosage Regimen, and Target Patient Population
Table 6.3 CAR-T Cell Therapy: Preclinical Pipeline
Table 6.4 List of CAR-T Cells Developers
Table 10.1 Leading CAR-T Cell Therapy Developers
Table 10.2 Autolus: Company Profile
Table 10.3 bluebird Bio: Company Profile
Table 10.4 Bristol Myers Squibb: Company Profile
Table 10.5 CARsgen Therapeutics: Company Profile
Table 10.6 Cellectis: Company Profile
Table 10.7 Gilead Sciences: Company Profile
Table 10.8 Innovative Cellular Therapeutics: Company Profile
Table 10.9 Noile-Immune Biotech: Company Profile
Table 10.10 Novartis: Company Profile
Table 10.11 Sinobioway Cell Therapy: Company Profile
Table 10.12 Takara Bio: Company Profile
Table 10.13 Wellington Zhaotai Therapies: Company Profile
Table 11.1 CAR T Cell Therapy: List of Partnerships and Collaborations, 2000-2022
Table 12.1 CAR T Cell Therapies: Funding and Investments, 2018-2024
Table 12.2 CAR T Cell Therapies: Summary of Investments
Table 13.1 Patent Analysis: Prominent CPC Sections
Table 13.2 Patent Analysis: Most Popular CPC Symbols
Table 13.3 Patent Analysis: List of Top CPC Symbols
Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.1 Assessment Strategies for Different Manufacturing Processes
Table 14.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 14.3 Cell Therapy Manufacturing: Companies with In-house Capabilities and Contract Manufacturers
Table 15.1 Price of Marketed Gene / Cell Therapies
Table 15.2 Price of Marketed Targeted Drugs
Table 15.3 CAR-T Cell Therapy: Expert Opinions on Pricing
Table 15.4 CAR-T Cell Therapy: Reimbursement Landscape
Table 21.1 CAR-T Cell Therapy: List of Forecasted Molecules
Table 25.1 CAR-T Cell Therapy:Distribution by Stage of Development
Table 25.2 CAR-T Cell Therapy: Distribution by Type ofTherapy
Table 25.3 CAR-T Cell Therapy: Distribution by Target Antigen
Table 25.4 CAR-T Cell Therapy: Distribution by Target Indication
Table 25.5 CAR-T Cell Therapy: Distribution by Target Therapeutic Area
Table 25.6 CAR-T Cell Therapy: Distribution by Stage of Development and Therapeutic Area
Table 25.7 CAR-T Cell Therapy: Distribution by Source of T- cells
Table 25.8 CAR-T Cell Therapy: Distribution by Stage of Development and Source of T- cells
Table 25.9 CAR-T Cell Therapy: Distribution by Route of Administration
Table 25.10 CAR-T Cell Therapy: Distribution by Dosage Regimen
Table 25.11 CAR-T Cell Therapy: Distribution by Target Patient Population
Table 25.12 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.14 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Table 25.15 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 25.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region wise)
Table 25.17 CAR-T Cell Therapy: Distribution by Location of Headquarters (Country wise)
Table 25.18 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Table 25.19 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Table 25.20 CAR-Construction: Distribution by Generation of CAR
Table 25.21 CAR-Construction: Distribution by Type of scFv Antibody Used
Table 25.22 CAR-Construction: Distribution by Type of Virus Used
Table 25.23 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Table 25.24 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Table 25.25 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2017-2024
Table 25.26 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year, Pre- 2017-2024
Table 25.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 25.28 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Table 25.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2017–2024
Table 25.30 Clinical Trial Analysis: Distribution by Trial Status
Table 25.31 Clinical Trial Analysis: Distribution by Patient Gender
Table 25.32 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 25.33 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 25.34 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 25.35 Clinical Trial Analysis: Distribution by Trial Purpose
Table 25.36 Clinical Trial Analysis: Distribution by Design Allocation
Table 25.37 Leading Industry Players: Distribution by Number of Registered Trials
Table 25.38 Leading Non-industry Players: Distribution by Number of Registered Trials
Table 25.39 Clinical Trial Analysis: Distribution of Clinical Trials by Status and Geography
Table 25.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 25.41 KOL Analysis: Distribution by Type of Organization
Table 25.42 KOL Analysis: Distribution by Affiliated Organization
Table 25.43 KOL Analysis: Distribution by Qualification
Table 25.44 CAR T-Cell Therapies:Geographical Distribution of KOLs
Table 25.45 Most Prominent KOLs: Distribution by RA Score
Table 25.46 Most Prominent KOLs:Comparison of RA Score with Third-Party Score
Table 25.47 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015-2022
Table 25.48 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.49 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 25.50 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 25.51 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.52 Partnership and Collaborations: Year-Wise Distribution by Type of Partner
Table 25.53 Most Popular Therapies:Distribution by Number of Partnerships
Table 25.54 Most Active Industry Players:Distribution by Number of Partnerships
Table 25.55 Most Active Non-IndustryPlayers: Distribution by Number of Partnerships
Table 25.56 Partnerships and Collaborations: Distribution byIntracontinental andIntercontinental Agreements
Table 25.57 Partnerships and Collaborations: Distribution byLocal and InternationalAgreements
Table 25.58 Funding and Investment: Cumulative Distribution of Instances by Year, Pre 2014–2024
Table 25.59 Funding and Investment: Cumulative Distribution of Amount Invested by Year, Pre-2014-2024 (USD Million)
Table 25.60 Funding and Investment: Distribution of Instances by Type of Funding
Table 25.61 Funding and Investment: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 25.62 Funding and Investment: Distribution by Amount Invested and Type of Funding Year Wise
Table 25.63 Funding and Investment: Distribution by Geography (Region)
Table 25.64 Funding and Investment: Distribution by Geography (Country)
Table 25.65 Most Active Players: Distribution by Lead Investors
Table 25.66 Most Active Players:Distribution by Number of Funding Instances
Table 25.67 Patent Analysis: Distributionby Type of Patent
Table 25.68 Patent Analysis: Distribution by Patent Publication Year, Pre-2018-2024
Table 25.69 Patent Analysis: Distribution by Patent Application Year
Table 25.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Pre-2018-2024
Table 25.71 Patent Analysis: Distribution by Patent Jurisdiction
Table 25.72 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 25.73 Leading Industry Players: Distribution by Number of Patents
Table 25.74 Leading Non-industry Players: Distribution by Number of Patents
Table 25.75 Leading Individual Assignees: Distribution by Number of Patents
Table 25.76 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 25.77 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 25.78 Patent Analysis: Distribution by Patent Age
Table 25.79 CAR-T Cell Therapy: Patent Valuation
Table 25.80 .Global CAR-T Cell Therapy Market, Conservative, Base and Optimistic Scenario, 2024-2035 (USD Million)
Table 25.81 CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024 and 2035
Table 25.82 CAR-T Cell Therapy Market for CD19: Forecasted Estimates (2024-2035) (USD Million)
Table 25.83 CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (2024-2035) (USD Million)
Table 25.84 CAR-T Cell Therapy Market for CD20: Forecasted Estimates (2024-2035) (USD Million)
Table 25.85 CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (2025-2035) (USD Million)
Table 25.86 CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (2028-2035) (USD Million)
Table 25.87 CAR-T Cell Therapy Market: Distribution by Target Indication, 2024 and 2035 (USD Million)
Table 25.88 CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.89 CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.90 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035) (USD Million)
Table 25.91 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.92 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma, Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.93 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035) (USD Million)
Table 25.94 CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035) (USD Million)
Table 25.95 CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.96 CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (2028-2035) (USD Million)
Table 25.97 CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035) (USD Million)
Table 25.98 CAR-T Cell Therapy Market for Renal transplantation: Forecasted Estimates (2030-2035) (USD Million)
Table 25.99 CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035) (USD Million)
Table 25.100 CAR-T Cell Therapy Market for Ovarian and endometrial Cancer: Forecasted Estimates (2028-2035) (USD Million)
Table 25.101 CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035) (USD Million)
Table 25.102 CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
Table 25.103 CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (2028-2035) (USD Million)
Table 25.104 CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024 and 2035
Table 25.105 CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035) (USD Million)
Table 25.106 CAR-T Cell Therapy Market in Europe: Forecasted Estimates (2024-2035) (USD Million)
Table 25.107 CAR-T Cell Therapy Market in Asia Pacific: Forecasted Estimates (2024-2035) (USD Million)
Table 25.108 CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (2024-2035) (USD Million)
Table 25.109 CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (2024-2035) (USD Million)
Table 25.110 CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (2024-2035) (USD Million)
Table 25.111 CAR-T Cell Therapy Marketfor Kymriah (Tisagenlecleucel-T): Sales Forecast, 2024-2035(USD Million)
Table 25.112 CAR-T Cell Therapy Marketfor Yescarta (axicabtageneciloleucel): Sales Forecast, 2024-2035 (USD Million)
Table 25.113 CAR-T Cell Therapy Marketfor Tecartus (BrexucabtageneAutoleucel): Sales Forecast,2024-2035 (USD Million)
Table 25.114 CAR-T Cell Therapy Marketfor Abecma (IdecabtageneVicleucel / bb2121): SalesForecast, 2024-2035 (USD Million)
Table 25.115 CAR-T Cell Therapy Marketfor CARVYKTI (LCAR-B38MCAR-T / JNJ-68284528 /Ciltacabtagene Autoleucel):Sales Forecast, 2024-2035, (USD Million)
Table 25.116 CAR-T Cell Therapy Marketfor BREYANZI (Lisocabtagene maraleucel,JCAR017): Sales Forecast, 2024-2035 (USD Million)
Table 25.117 CAR-T Cell Therapy Marketfor Carteyva (Relmacabtageneautoleucel / JWCAR029):Sales Forecast, 2024-2035, (USD Million)
Table 25.118 CAR-T Cell Therapy Marketfor NexCART: Sales Forecast,2024-2035, (USD Million)
Table 25.119 CAR-T Cell Therapy Marketfor Fucaso (EquecabtageneAutoleucel): Sales Forecast,2024-2035, (USD Million)
Table 25.120 CAR-T Cell Therapy Marketfor Inaticabtagene AutoleucelCNCT19 / HY001: Sales Forecast, 2024-2035 (USDMillion)
Table 25.121 CAR-T Cell Therapy Marketfor Zevorcabtagene autoleucel (CT053): Sales Forecast, 2024-2035 (USD Million)
Table 25.122 CAR-T Cell Therapy Marketfor CAR-BCMA T cells: SalesForecast, 2027-2035 (USD Million)
Table 25.123 CAR-T Cell Therapy Marketfor CAR-T-CD19 cells : SalesForecast, 2026-2035 (USD Million)
Table 25.124 CAR-T Cell Therapy Marketfor Descartes-08: SalesForecast, 2029-2035 (USD Million)
Table 25.125 CAR-T Cell Therapy Marketfor Zamtocabtagene Autoleucel (MB-CART2019.1): SalesForecast, 2028-2035 (USD Million)
Table 25.126 CAR-T Cell Therapy Marketfor CAR-T ddBCMA: SalesForecast, 2029-2035 (USD Million)
Table 25.127 CAR-T Cell Therapy Marketfor CRG-02121 cells: SalesForecast, 2030-2035 (USD Million)
Table 25.128 CAR-T Cell Therapy Marketfor CT041: Sales Forecast, 2030-2035, (USD Million)
Table 25.129 CAR-T Cell Therapy Marketfor ALLO-501A / ALLO-501:Sales Forecast, 2032-2035, (USD Million)
Table 23.130 CAR-T Cell Therapy Marketfor ALLO-605: Sales Forecast,2028-2035 (USD Million)
Table 25.131 CAR-T Cell Therapy Marketfor Descartes-25: SalesForecast, 2029-2035 (USD Million)
Table 25.132 CAR-T Cell Therapy Marketfor AUTO1: Sales Forecast,2029-2035 (USD Million)
Table 25.133 CAR-T Cell Therapy Marketfor AUTO3 (CD19/22 CAR-T): Sales Forecast, 2025-2035 (USD Million)
Table 25.134 CAR-T Cell Therapy Marketfor AUTO4 (CD19/22 CAR-T) : Sales Forecast, 2029-2035 (USD Million)
Table 25.135 CAR-T Cell Therapy Marketfor CD19-CAR-T: SalesForecast, 2026-2035 (USD Million)
Table 25.136 CAR-T Cell Therapy Marketfor Humanized CD19-CAR-T:Sales Forecast, 2028-2035 (USD Million)
Table 25.137 CAR-T Cell Therapy Marketfor IM19 CAR-T: SalesForecast, 2027-2035 (USD Million)
Table 25.138 CAR-T Cell Therapy Marketfor CCT301 CAR-T: SalesForecast, 2028-2035 (USD Million)
Table 25.139 CAR-T Cell Therapy Marketfor CARCIK-CD19: SalesForecast, 2028-2035 (USD Million)
Table 25.140 CAR-T Cell Therapy Marketfor CD123 CAR-T cells: SalesForecast, 2028-2035 (USD Million)
Table 25.141 CAR-T Cell Therapy Marketfor BCMA CAR-T: SalesForecast, 2028-2035 (USD Million)
Table 25.142 CAR-T Cell Therapy Marketfor CD19/CD22-CAR-T: Sales Forecast, 2029-2035 (USD Million)
Table 25.143 CAR-T Cell Therapy Marketfor GC012F (Dual CAR-BCMA-19): Sales Forecast, 2029-2035 (USD Million)
Table 25.144 CAR-T Cell Therapy Marketfor CD19/CD20-CART: SalesForecast, 2030-2035 (USD Million)
Table 25.145 CAR-T Cell Therapy Marketfor CD7 CAR-T: SalesForecast, 2029-2035 (USD Million)
Table 25.146 CAR-T Cell Therapy Marketfor Anti-FLT3 CAR-T /TAA05: Sales Forecast, 2030-2035 (USD Million)
Table 25.147 CAR-T Cell Therapy Marketfor Anti-ALPP CAR-T Cells:Sales Forecast, 2028-2035 (USD Million)
Table 25.148 CAR-T Cell Therapy Marketfor WU CART 007: SalesForecast, 2030-2035 (USD Million)
Table 25.149 CAR-T Cell Therapy Marketfor CTX110: Sales Forecast,2030-2035 (USD Million)
Table 25.150 CAR-T Cell Therapy Market for TX200-TR101: SalesForecast, 2030-2035 (USD Million)
Table 25.151 CAR-T Cell Therapy Market for ALETA-001: SalesForecast, 2030-2035 (USD Million)
Table 25.152 CAR-T Cell Therapy Market for PBCAR0191: SalesForecast, 2030-2035 (USD Million)
Table 25.153 CAR-T Cell Therapies Market: Distribution by Key Players
Table 25.154 CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, 2024-2035 (USD Million)
Table 25.155 CAR-T Cell Therapies Market: Janssen Sales Forecast, 2024-2035 (USD Million)
Table 25.156 CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, 2024-2035 (USD Million)
Table 25.157 CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, 2024-2035 (USD Million)
Table 25.158 CAR-T Cell Therapies Market: Novartis Sales Forecast, 2024-2035 (USD Million)

List Of Companies And Organizations

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. A2 Biotherapeutics
  2. AbClon
  3. AbelZeta Pharma
  4. Ac?badem Labcell
  5. Actavis
  6. Adage Capital Partners
  7. Adaptimmune
  8. Adicet Bio
  9. AffyImmune Therapeutics
  10. Alaunos Therapeutics
  11. Aleta Biotherapeutics
  12. Alexandria Venture Investments
  13. Allogene Therapeutics
  14. Allucent
  15. Anixa Biosciences
  16. Arbele
  17. Arcellx
  18. Astrazeneca
  19. Atara Biotherapeutics
  20. Aurora Biopharma
  21. Autolus
  22. AvenCell Therapeutics
  23. Baylor College of Medicine
  24. Beam Therapeutics
  25. Beijing DCTY Biotech
  26. Beijing Doing Biomedical
  27. Beijing HuiNengAn Biotech
  28. Beijing Immunochina Medical Science & Technology
  29. Beijing Mario Biotech
  30. Beijing Yongtai Ruike Biotechnology 
  31. Beike Biotechnology
  32. Bellicum Pharmaceuticals
  33. Bio4t2
  34. Bioceltech Therapeutics
  35. BioClever
  36. Bio-Gene Technology
  37. BioNTech
  38. Bioray Laboratories
  39. Biosceptre
  40. Biosyngen
  41. bluebird bio
  42. BoYuan RunSheng Pharma (Hangzhou)
  43. Bristol Myers Squibb
  44. Cabaletta Bio
  45. Calibr
  46. California Institute for Regenerative Medicine
  47. Carbiogene Therapeutics
  48. CARGO Therapeutics
  49. Caribou Biosciences
  50. Carina Biotech
  51. Caring Cross
  52. Carisma Therapeutics
  53. CARsgen Therapeutics
  54. Cartesian Therapeutics
  55. Cartherics
  56. CASI Pharmaceuticals
  57. Celgene Corporation
  58. CellabMED
  59. Cellectis
  60. Cellular Biomedicine Group
  61. Celularity
  62. Celyad Oncology
  63. Chengdu USino Technology Biology
  64. Chimeric Therapeutics
  65. China Immunotech (Beijing) Biotechnology
  66. Chinese Academy of Medical Sciences
  67. Chongqing Precision Biotech
  68. Chongqing Sidemu Biotech
  69. Chongqing University Cancer Hospital
  70. City of Hope Medical Center
  71. Cormorant Asset Management
  72. CRISPR Therapeutics
  73. CSPC Pharmaceutical 
  74. Curocell
  75. CytoMed Therapeutics
  76. Daiichi Sankyo
  77. EdiGene
  78. Elicera Therapeutics
  79. Elpis Biopharmaceuticals
  80. Essen BioTech
  81. Eugia Pharma Specialities
  82. Eureka Therapeutics
  83. Eutilex
  84. Fate Therapeutics
  85. Fidelity Management & Research
  86. First Affiliated Hospital of Zhejiang University
  87. Formula Pharmaceuticals
  88. Fosun Pharma
  89. Fundamenta Therapeutics
  90. Genentech
  91. Genmab
  92. Gilead Sciences
  93. Gracell Biotechnologies
  94. Guangdong Zhaotai Cell Biotechnology 
  95. Guangdong Zhaotai InVivo Biomedicine
  96. Guangzhou Anjie Biomedical Technology
  97. Guangzhou Bio-gene Technology
  98. Guangzhou Bioresette Biomedical Technology  
  99. H. Lee Moffitt Cancer Center and Research Institute
  100. Hangzhou Cheetah Cell Therapeutics 
  101. Hebei Senlang Biotechnology
  102. Henan Hualong Biotechnology
  103. Hoosier Cancer Research Network
  104. Hrain Biotechnology
  105. HuaDao (Shanghai) Biomedical
  106. Hunan Zhaotai Yongren Medical Innovation
  107. IASO Biotherapeutics
  108. iCAR Bio Therapeutics
  109. iCell Gene Therapeutics
  110. ICON
  111. IDION
  112. IIT MediTech (Jiangsu)
  113. ImmPACT Bio
  114. Immuneel Therapeutics
  115. ImmunoACT
  116. Imugene
  117. Incyte
  118. Innovative Cellular Therapeutics
  119. Innovent Biologics
  120. Invectys
  121. Janssen
  122. Janus Henderson Investors
  123. Johnson & Johnson
  124. Juno Therapeutics (Acquired by Bristol-Myers Squibb company)
  125. Juventas Cell Therapy
  126. JW Therapeutics
  127. KAEDI
  128. Karolinska Institute
  129. Kecellitics Biotech
  130. Kite Pharma (Acquired by Gilead Sciences)
  131. Kuur Therapeutics
  132. Kyverna Therapeutics
  133. Legend Biotech
  134. Leiden University Medical Center
  135. Leman Biotech
  136. Lentigen Technology (a subsidiary of Miltenyi Biotech)
  137. Leucid Bio
  138. Lilly Asia Ventures
  139. Luminary Therapeutics
  140. Lyell Immunopharma
  141. Marino Biotechnology
  142. MD Anderson Cancer Center
  143. Medisix Therapeutics
  144. Memorial Sloan Kettering Cancer Center
  145. Merck
  146. Miltenyi Biomedicine
  147. Miltenyi Biotec
  148. Minerva Biotechnologies
  149. Mustang Bio
  150. Nanjing Bioheng Biotech
  151. Nanjing Blue Shield Biotech
  152. National Cancer Institute (NCI)
  153. National Institutes of Health
  154. Nektar Therapeutics
  155. Nexcella
  156. Nkarta
  157. Noile-Immune Biotech
  158. Novartis
  159. Novatim Immune Therapeutics
  160. Oncternal Therapeutics
  161. OneChain Immunotherapeutics
  162. ONK Therapeutics
  163. oNKo-innate
  164. Ono Pharmaceutical
  165. OrbiMed
  166. Orca Biosystems
  167. Oxford Biomedica
  168. PELL Biotech Pharmaceutical 
  169. PeproMene Bio
  170. PersonGen BioTherapeutics (Suzhou)
  171. Pfizer
  172. Poseida Therapeutics
  173. Precigen
  174. Precision BioSciences
  175. Prescient Therapeutics
  176. Prostate Cancer Foundation
  177. Protheragen
  178. Quell Therapeutics
  179. RA Capital Management
  180. Redmile Group
  181. Regeneron
  182. Roche
  183. Sabz Biomedicals
  184. Sana Biotechnology
  185. Sangamo Therapeutics
  186. Servier
  187. Shanghai Bioray Laboratory
  188. Shanghai Cell Therapy Group
  189. Shanghai First Song Therapeutics
  190. Shanghai Longyao Biotechnology
  191. Shanghai Ming Ju Biotechnology
  192. Shanghai OriginCell Therapeutics
  193. Shanghai PerHum Therapeutics
  194. Shanghai Pharmaceuticals
  195. Shanghai Simnova Biotechnology
  196. Shanghai Ultra-T Immune Therapeutics
  197. Shanghai Unicar-Therapy Bio-medicine Technology
  198. Shenzhen Binde Biotechnology
  199. Shunxi 
  200. Sichuan Kelun-Biotech Biopharmaceutical
  201. Simcere Pharmaceutical
  202. Sinobioway Cell Therapy
  203. Soochow T-Maximun Biotechnology
  204. Sorrento Therapeutics
  205. Suzhou Fundamenta Therapeutics
  206. Suzhou Immunofoco Biotechnology
  207. Syncopation Life Sciences
  208. Synthekine
  209. Takara Bio
  210. Takeda
  211. Tasly Pharmaceutical Group
  212. TC BioPharm
  213. TCRCure Biopharma
  214. Tempus
  215. Tessa Therapeutics
  216. The First Affiliated Hospital of Soochow University
  217. The Fourth Hospital of Hebei Medical University
  218. The Pregene (ShenZhen) Biotechnology
  219. TiCARos
  220. Timmune Biotech
  221. Tmunity Therapeutics
  222. Umoja BioPharma
  223. Union Stem Cell & Gene Engineering
  224. University of Pennsylvania
  225. UTC Therapeutics
  226. UWELL Biopharma
  227. VCN Biosciences
  228. venBio
  229. Vivo Capital
  230. Vor Biopharma
  231. Wellcome Trust
  232. Wellington Zhaotai Therapies
  233. Wugen
  234. Wuhan Si'an Medical Technology
  235. WuXi AppTec
  236. Yake Biotechnology
  237. Yake Biotechnology
  238. Zeno Therapeutics
  239. Zhejiang Qixin Bio 

 
 

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com